Caris, Ontada form collaboration to advance molecular research, cancer care

The challenge of making the move from conversational AI to autonomous scientific discovery
Advancing from level II to level III AI agents in precision medicine

Artificial intelligence is rapidly transforming biomedical research and healthcare. Large language models, foundation models, and AI agents are increasingly being deployed to assist with data interpretation, literature review, clinical decision support, and translational research.

July 10, 2026

Vol.52 No.27

By Enrique Velazquez-Villarreal

Clinical Trials & Tribulations

Protecting the cure: Why the future of radiation oncology must be precision-guided

Radiation therapy has been a cornerstone of cancer care since 1896. For more than a century, the central challenge has remained unchanged: How to eradicate tumors while preserving the normal tissues that allow patients not only to survive, but to thrive after treatment.

Sustaining community oncology through nonprofit structures and shared technology infrastructure

Independent oncology practices are facing unprecedented operational strain as reimbursement pressures, cybersecurity obligations, capital needs, and staffing challenges converge.

Alice Soragni joins CU Anschutz to launch functional personalized medicine initiative

Alice Soragni, an expert in patient-derived tumor organoids and functional precision oncology, has joined the University of Colorado Anschutz.

February 20, 2026

Vol.52 No.07

Drugs & Targets

Labcorp and Roche collaborate to expand access to advanced precision testing

Labcorp announced its first U.S. commercial laboratory with an agreement to implement Roche’s cobas Mass Spec solution. This collaboration introduces fully automated mass spectrometry into routine clinical practice—accelerating turnaround times, improving accuracy, and expanding access to advanced diagnostics for patients and providers nationwide.

January 30, 2026

Vol.52 No.04

Drugs & Targets

SOPHiA GENETICS partners with MD Anderson on AI-driven precision oncology

SOPHiA GENETICS and The University of Texas MD Anderson Cancer Center have entered into a collaboration to accelerate data-driven cancer care through new tools that can accurately analyze, interpret, and translate diagnostic results into clinical practice.

January 09, 2026

Vol.52 No.1

Caris, Ontada form collaboration to advance molecular research, cancer care

YOU MAY BE INTERESTED IN

The challenge of making the move from conversational AI to autonomous scientific discovery
Advancing from level II to level III AI agents in precision medicine

Protecting the cure: Why the future of radiation oncology must be precision-guided

Sustaining community oncology through nonprofit structures and shared technology infrastructure

Alice Soragni joins CU Anschutz to launch functional personalized medicine initiative

Labcorp and Roche collaborate to expand access to advanced precision testing

SOPHiA GENETICS partners with MD Anderson on AI-driven precision oncology

Renew today!

Subscriber content

Never miss an issue!

Login

Caris, Ontada form collaboration to advance molecular research, cancer care

YOU MAY BE INTERESTED IN

The challenge of making the move from conversational AI to autonomous scientific discoveryAdvancing from level II to level III AI agents in precision medicine

Protecting the cure: Why the future of radiation oncology must be precision-guided

Sustaining community oncology through nonprofit structures and shared technology infrastructure

Alice Soragni joins CU Anschutz to launch functional personalized medicine initiative

Labcorp and Roche collaborate to expand access to advanced precision testing

SOPHiA GENETICS partners with MD Anderson on AI-driven precision oncology

Never miss an issue!

Login

The challenge of making the move from conversational AI to autonomous scientific discovery
Advancing from level II to level III AI agents in precision medicine